Lupin Limited has informed the Exchange regarding a press release dated October 03, 2025, titled "Lupin Launches Liraglutide Injection in the United States".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has launched Liraglutide Injection in the US market, as per a press release dated October 3, 2025. Liraglutide is a GLP-1 receptor agonist used for the treatment of type 2 diabetes, a fast-growing therapy area in the US. The launch follows the required USFDA approval and adds a complex injectable product to Lupin's US generics portfolio. This strengthens Lupin's presence in the high-value US diabetes segment, where it already markets other medications. The company had earlier received approval for this product and has now made it commercially available through its US distribution channels.
Positive for the company — expands Lupin's US product portfolio in a high-demand therapy area, potentially adding meaningful revenue, though the competitive GLP-1 market may limit pricing power and uptake speed.